Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study of Nebulized Human Normal Immunoglobulin (CSL787) for Adults with Non-cystic Fibrosis Bronchiectasis to Find Best Dose and Test Safety

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical study focuses on Non-cystic Fibrosis Bronchiectasis, a condition where the airways in the lungs become permanently widened and damaged. The study will test a new inhaled medication called CSL787, which contains human normal immunoglobulin (a type of protein that helps fight infections), compared to a placebo.

The purpose of this research is to evaluate how well CSL787 works in preventing flare-ups of the disease and to determine the most effective dose. The medication will be given through a nebulizer, which is a device that turns liquid medicine into a fine mist that can be inhaled into the lungs. The study will last for up to 12 months.

During the study, participants will be randomly assigned to receive either different doses of CSL787 or a placebo through the nebulizer. The study will monitor how long it takes before participants experience their first disease flare-up and will also track other aspects of their lung health and overall well-being. This is a double-blind study, which means neither the participants nor the doctors conducting the study will know who is receiving which treatment.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial screening

    Your eligibility will be evaluated based on the following criteria:

    - Age between 18 to 85 years

    - Confirmed diagnosis of Non-cystic Fibrosis Bronchiectasis (NCFB) through chest CT scan

    - If your chest CT scan is older than 12 months, a new scan will be performed

    - Lung function test showing FEV1 greater than 35% of predicted value and at least 1 liter

  2. Step 2

    Medical history review

    Your medical history must include either:

    - At least 2 documented chest infections requiring antibiotics in the past year, or

    - 1 chest infection requiring antibiotics and a St. George's Respiratory Questionnaire score above 40

  3. Step 3

    Treatment phase

    You will receive either:

    - CSL787 (human normal immunoglobulin) through inhalation using a nebulizer, or

    - Placebo solution for inhalation

    The treatment will be randomly assigned and neither you nor your doctor will know which treatment you are receiving

  4. Step 4

    Monitoring phase

    During the study, the following will be monitored:

    - Time until your first chest infection

    - Number of chest infections per year

    - Changes in your respiratory symptoms

    - Changes in bacteria levels in your sputum

    - Any side effects or adverse events

Who can join the trial?

7 criteria

  • Must be aged between 18 and 85 years old
  • Must have a confirmed diagnosis of Non-cystic Fibrosis Bronchiectasis (NCFB) through a chest CT scan (a special type of X-ray that creates detailed images of your lungs) within the last 12 months before joining the study. If you don't have a recent scan, one will be done during screening
  • Must have experienced at least one of these in the past year:
    • 2 or more lung infections requiring treatment with oral or intravenous antibiotics, OR
    • 1 lung infection requiring antibiotics AND a score higher than 40 on a breathing-related quality of life questionnaire (SGRQ)
    • Must have lung function tests showing:
      • More than 35% of normal breathing capacity (FEV1 - the amount of air you can forcefully exhale in one second)
      • Ability to forcefully exhale at least 1 liter of air in one second
      • Can be taking other medications for NCFB (such as maintenance macrolides or DPP-1 inhibitors), as long as you had at least one infection while taking these medications for 3 or more months at a stable dose

Who cannot join the trial?

14 criteria

  • Age below 18 or above 75 years
  • Having cystic fibrosis (an inherited condition affecting the lungs and digestive system)
  • Current pregnancy or breastfeeding
  • Having a known allergy to immunoglobulins (antibodies used in the treatment)
  • Active lung infection at the time of screening
  • Participation in another clinical trial within the last 30 days
  • History of severe allergic reactions to medical treatments
  • Significant kidney or liver disease
  • Current smoking or having quit smoking within the last 6 months
  • Unable to use a nebulizer properly (a device that turns liquid medicine into a mist for inhalation)
  • Having received antibiotics for respiratory infection within the last 4 weeks
  • History of immunodeficiency (weakened immune system)
  • Major surgery within the last 3 months
  • Any condition that the study doctor considers would make participation unsafe
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

CSL787 (human normal immunoglobulin for nebulization) is a medication that is delivered through a nebulizer, which turns the medicine into a fine mist that can be inhaled. This treatment is being studied for people with non-cystic fibrosis bronchiectasis, a condition where the airways become damaged and widened. The medication contains antibodies (immune system proteins) that may help protect against lung infections and reduce inflammation in the airways.

What is already known about the treatment

CSL787 – A nebulized form of human normal immunoglobulin that is administered through inhalation using a nebulizer device. This investigational medication is currently being studied in Phase 2b clinical trials for the treatment of Non-cystic Fibrosis Bronchiectasis, a chronic respiratory condition. The drug works by delivering immunoglobulins directly to the airways, where they can help support the immune system and potentially reduce inflammation in the bronchial tubes. As a biological therapy belonging to the immunoglobulin class of medications, CSL787 represents a novel approach to treating bronchiectasis by targeting the underlying immune mechanisms involved in the disease process.

Investigated diseases

Non-cystic Fibrosis Bronchiectasis – A chronic respiratory condition characterized by permanent widening of the airways (bronchi) in the lungs. In this condition, the airways become damaged and scarred, leading to areas where mucus can accumulate. The damaged airways lose their ability to clear mucus effectively, creating an environment where bacteria can grow. This results in recurring chest infections and inflammation, causing symptoms such as chronic cough with mucus production, shortness of breath, and recurrent chest infections. The condition is distinct from bronchiectasis caused by cystic fibrosis and can be triggered by various factors including previous severe infections or underlying inflammatory conditions.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-518821-13-00Protocol codeCSL787_2001Estimated enrolment459 patientsSponsorCSL Behring LLC

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).